Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. Its product candidates also comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor IIb, which is in Phase I clinical trials to treat patients with gastric or gastroesophageal junction and bladder cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 as a monotherapy in various cancers. The company's FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with bluebird bio, Inc., Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600
Debt
Debt-to-Equity RatioN/A
Current Ratio9.79
Quick Ratio9.79
Price-To-Earnings
Trailing P/E Ratio-3.22
Forward P/E Ratio-3.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$39.51 million
Price / Sales15.43
Cash FlowN/A
Price / CashN/A
Book Value$7.80 per share
Price / Book2.22
Profitability
EPS (Most Recent Fiscal Year)($5.38)
Net Income$-150,220,000.00
Net Margins-221.74%
Return on Equity-44.36%
Return on Assets-36.14%
Miscellaneous
Employees216
Outstanding Shares35,210,000
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The biotechnology company earned $32.49 million during the quarter, compared to analysts' expectations of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. View Five Prime Therapeutics' Earnings History.
What price target have analysts set for FPRX?
7 analysts have issued 12 month target prices for Five Prime Therapeutics' shares. Their predictions range from $17.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $34.7143 in the next year. View Analyst Ratings for Five Prime Therapeutics.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Clovis Oncology (CLVS), Xencor (XNCR), Enanta Pharmaceuticals (ENTA), TESARO (TSRO), Heron Therapeutics (HRTX), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Insmed (INSM), Akcea Therapeutics (AKCA), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Prestige Brands (PBH), Corcept Therapeutics (CORT) and Akorn (AKRX).
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Dr. Lewis T. Williams, Founder & Exec. Chairman (Age 69)
- Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 49)
- Dr. Kevin P. Baker, Sr. VP of Devel. Sciences (Age 57)
- Dr. Peder K. Jensen, Advisor & Director (Age 63)
- Mr. Jeff P. Coon, Sr. VP of HR (Age 55)
Has Five Prime Therapeutics been receiving favorable news coverage?
News headlines about FPRX stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a coverage optimism score of 0.24 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.50 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Five Prime Therapeutics' major shareholders?
Five Prime Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.56%), Victory Capital Management Inc. (3.04%), Dimensional Fund Advisors LP (2.96%), BB Biotech AG (2.78%), Rock Springs Capital Management LP (1.66%) and Northern Trust Corp (1.05%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.
Which institutional investors are selling Five Prime Therapeutics stock?
Which institutional investors are buying Five Prime Therapeutics stock?
FPRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, BB Biotech AG, DekaBank Deutsche Girozentrale, Victory Capital Management Inc., Millennium Management LLC, UBS Group AG and State of Wisconsin Investment Board. View Insider Buying and Selling for Five Prime Therapeutics.
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $17.31.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $598.91 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.
MarketBeat Community Rating for Five Prime Therapeutics (FPRX)
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
